Ipsen (FR:IPN) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Ipsen’s Bylvay® demonstrates promising long-term efficacy and safety in treating rare cholestatic liver diseases, including PFIC and ALGS, with significant improvements in symptoms such as itch severity and serum bile acid levels over 72 weeks. The treatment has also shown benefits in patient growth and sleep quality, with most adverse events reported as mild or moderate. Ipsen aims to lead advancements in managing these challenging conditions.
For further insights into FR:IPN stock, check out TipRanks’ Stock Analysis page.
